Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver - PubMed (original) (raw)

Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver

J G Fan et al. World J Gastroenterol. 2001 Oct.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Figure 1

The expression of hepatic PAI-1 mRNA.1, 2: control group; 3, 4, 5: model group; M: marker

Figure 2

Figure 2

The expression of hepatic β-action mRNA.1, 2: control group; 3, 4, 5: model group; M: marker

Similar articles

Cited by

References

    1. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med. 2000;32 Suppl 1:78–84. - PubMed
    1. Nordt TK, Peter K, Ruef J, Kübler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost. 1999;82 Suppl 1:14–18. - PubMed
    1. Mezzano D, Muñoz X, Martínez C, Cuevas A, Panes O, Aranda E, Guasch V, Strobel P, Muñoz B, Rodríguez S, et al. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost. 1999;81:913–917. - PubMed
    1. Inuzuka S, Ueno T, Torimura T, Tamaki S, Sugawara H, Sakata R, Kusaba N, Sata M, Tanikawa K. The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol. 1997;32:1052–1060. - PubMed
    1. Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, Palareti G, Gramantieri L, Gaiani S, Burroughs AK, et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology. 2000;31:349–357. - PubMed

MeSH terms

Substances

LinkOut - more resources